FDA Finalizes Stricter NDI Guidance, Compliance Costs Forecast to Rise

By: Herbuno News Desk

FDA Tightens Scrutiny on "Grandfathered" Supplement Ingredients

The U.S. Food and Drug Administration (FDA) has finalized its revised draft guidance on New Dietary Ingredient (NDI) notifications, signaling a major regulatory shift for supplement manufacturers. This updated framework is part of the FDA’s strategic effort to modernize the 1994 Dietary Supplement Health and Education Act (DSHEA) and enhance consumer safety.

The new guidance places intense focus on traceability and the sufficiency of data supporting pre-1994 “grandfathered” status claims for ingredients. Companies must now provide highly specific documentation for demonstrating historical use, shifting away from generalized assertions.

Analysts suggest the heightened evidentiary standards will substantially increase compliance burdens across the supply chain. Specifically, the FDA emphasized that novel processing techniques—even when applied to established substances like Ceramides derived from ingredients such as Rice Bran—will now likely necessitate a full NDI submission. This increased scrutiny also extends to unique or newly refined botanical extracts. Experts estimate that compliance costs for required NDI submissions could rise by 15-20% within the next fiscal year.

For a detailed analysis of the final guidance, stakeholders can refer to reports from Nutraceuticals World or review the official documentation on the FDA Dietary Supplements Portal.